Glycemic patterns and factors associated with post-hemodialysis hyperglycemia among end-sStage-renal disease patients undergoing maintenance hemodialysis by Yusof Khan, Abdul Hanif Khan et al.
INTRODUCTION 
Over two million people worldwide currently on renal 
replacement therapy have Type 2 Diabetes Mellitus 
(T2DM), the leading cause of end-stage-renal-disease 
(ESRD).1,2 In Malaysia T2DM accounted for 61% of new 
dialysis patients.3
Glycemic patterns among diabetic patients with ESRD 
(DM-ESRD) whether or not on hemodialysis differ from 
those of diabetic patients without ESRD as glucose 
metabolism changes with decline in kidney function. 
Glycemic fluctuations are more pronounced among 
DM-ESRD as they may experience hemodialysis induced 
hypoglycemia and hyperglycemia.4,5 Furthermore, 
hemodialysis per se is an independent risk factor for 
glycemic fluctuations as glucose is freely filtered and 
insulin is absorbed during hemodialysis.6 
Fluctuations in glucose metabolism have proven to be 
detrimental in DM-ESRD as they leads to poor survival 
mainly owing to cardiovascular complications.7 This was 
demonstrated by a six-year cohort study among DM-
ESRD patients that showed a U-shape association between 
glycemic control (HbA1c <6% and >8%) and a decrease in 
overall survival.8 This U-shape association might indicate 
that chronic hyperglycemia is not the only indicator for 
morbidity and mortality, but also hypoglycemia and glucose 
fluctuations.7,8 Furthermore, many studies have shown 
glycemic variability (GV) as an independent risk factor for 
both morbidity and mortality among diabetic populations.9 
Therefore, this study focused on glycemic patterns on 
hemodialysis days and non-hemodialysis days among 
ESRD patients. We also looked at post-hemodialysis 
rebound hyperglycemia (PHH), and its associated factors, 
as identifying these factors is hoped to optimize the 
management of this high-risk group.
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Abstract
Introduction. Chronic and post-prandial hyperglycemia are independent risk factors for diabetic complications. 
Glycemic patterns among hemodialysis end-stage-renal-disease (ESRD) differ as glucose metabolism changes with 
declining kidney function with more pronounced glycemic fluctuations. The objectives of this study are to determine 
glycemic patterns on hemodialysis days, the magnitude of post-hemodialysis rebound hyperglycemia (PHH) and their 
associated factors. 
Methodology. 148 patients on hemodialysis were analysed, 91 patients had end-stage-diabetic-renal disease 
(DM-ESRD), and 57 patients had end-stage-non-diabetic renal disease (NDM-ESRD). Glycemic patterns and PHH 
data were obtained from 11-point and 7-point self-monitoring blood glucose (SMBG) profiles on hemodialysis and 
non-hemodialysis days. PHH and its associated factors were analysed with logistic regression. 
Results. Mean blood glucose on hemodialysis days was 9.33 [SD 2.7] mmol/L in DM-ESRD patients compared to 6.07 
[SD 0.85] mmol/L in those with NDM-ESRD (p<0.001). PHH occurred in 70% of patients and was more pronounced in 
DM-ESRD compared to NDM-ESRD patients (72.5% vs 27.5%; OR 4.5). Asymptomatic hypoglycemia was observed 
in 18% of patients. DM-ESRD, older age, previous IHD, obesity, high HbA1c, elevated highly-sensitive CRP and 
low albumin were associated with PHH. 
Conclusion. DM-ESRD patients experienced significant PHH in our cohort. Other associated factors include older 
age, previous IHD, obesity, high HbA1c, elevated hs-CRP and low albumin.
Key words: renal dialysis, glycemic variability, diabetes complications, hyperglycemia, risk factors
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METHODOLOGY 
Study design and sample population 
One hundred and fifty ESRD patients on maintenance 
hemodialysis (93 DM-ESRD patients and 57 NDM-ESRD 
patients), were recruited in this cross-sectional study. 
Sample size was calculated by multiple logistic regression 
using G Power software.10 Based on a study by Jin Y.P, 
2015 we estimate the occurrence of post haemodialysis 
hyperglycemia among the DM-ESRD patients to be 
threefold that of NDM-ESRD patients.11 We considered a 
model with one binary covariate X with event rate under 
Ho, p1 = 0.13 and the event rate under X = 1, p2 = 0.40, giving 
the odds ratio of ~ 4.5. We further assumed R2 = 0.1, and an 
imbalanced design ratio of 2:1 between the 2 groups. The 
estimating sample size necessary to achieve a two-sided 
test with alpha of 0.05 and power of at least 80% was 102. 
Considering a 30% non-response rate, the final sample 
size was 146 rounded to 150.
Inclusion criteria were: adults age more than 18 with or 
without diabetes, patients on maintenance hemodialysis 
for at least three months. NDM-ESRD patients were 
included to observe the effect of hemodialysis on non-
diabetic patients. Exclusion criteria were: Type 1 diabetes 
mellitus patients, presence of acute inflammatory state, 
hemoglobinopathy, history of blood transfusion or 
hospitalization for the last three months, and diagnosis 
of malignancy.
Socio-demographics, co-morbidities and laboratory 
data 
Socio-demographic characteristics, clinical data, co-
morbidities and medication lists were obtained using a 
standardized questionnaire. At recruitment, baseline blood 
investigations were taken: glycated hemoglobin –A1c 
(HbA1c), lipid profile, renal profile, albumin, hemoglobin, 
inflammatory markers, iron studies and bone parameters.
Glucose monitoring on hemodialysis and non-
hemodialysis days 
Glucose values in our study were obtained from capillary 
glucose measurements using capillary glucometers 
(Bayer contour plus®). Patients were taught to self-
measure the capillary glucose and were assisted during 
the hemodialysis sessions. Patients were advised to 
record the glucose values and medications taken and 
were also educated to recognize hypoglycemic signs and 
symptoms. On hemodialysis days, a 11-point capillary 
self-monitoring glucose (SMBG) profile was obtained with 
hourly capillary glucose taken during the hemodialysis 
sessions. On non-hemodialysis days, 7 points SMBG 
were taken by the patients. Patients were not required to 
fast during hemodialysis but were asked to report and 
food consumed that was out of their ordinary diet.
Statistical analysis 
Analyses were performed using R studio version 
1.0.153 using the STATS package for statistical analysis. 
In descriptive statistics, categorical data results were 
described as count and percentage while continuous data 
in mean and standard deviation (SD). Overall glycemic 
profile, specifically looking, as post hemodialysis glucose 
value was measured in terms of means glucose ± SD. The 
data was checked for normality visually by histogram 
and statistically using the Shapiro Wilk test. For bivariate 
analysis, a chi squared test was used for comparing 
categorical data. An independent t-test was used to 
compare means between the groups as the data was 
normally distributed. The assumption of equal variance 
was met using Levene’s test. The level of significance was 
set at 0.05. In order to determine the association between 
PHH with clinical and laboratory variables, simple 
logistic regression was done to derive the crude odd 
ratio. Subsequently, the variables which were significant 
at p < 0.15 were included in the final multivariate logistic 
regression analysis. All the crude and adjusted odds ratios 
were presented with 95% confidence intervals. For missing 
data, the Listwise deletion method was used.
RESULTS 
Socio-demographics, co-morbidities and laboratory 
data analysis 
From the total of 150 patients recruited, 148 patients data 
were included in the final analysis due to missing data 
from two patients. Table 1 demonstrates the baseline 
sociodemographics and co-morbidities of our cohort. 
Ninety-one (61.5%) patients had diabetes with a mean 
age of 57.6 years and mean duration of diabetes of 16.4 
years. Mean duration of hemodialysis in DM-ESRD and 
NDM-ESRD patients were 3.8 and 4.5 years, respectively. 
Body mass index (BMI) in the majority of patients was 
Obese Class 1. The difference in socio-demographics and 
co-morbidities among both groups were not statistically 
significant apart from DM-ESRD patients having higher 
BMI and higher prevalence of smoking among NDM-ESRD 
patients. Ischemic heart disease (IHD) was present in 
one-fourth of the patients. Blood pressure control was 
poor with only 16 (10.7%) of DM-ESRD and 47 (31.3%) of 
NDM-ESRD patients achieving pre and post hemodialysis 
target blood pressure of less or equal to 130/80 mmHg.
In terms of medications, 50 (54.9%) of diabetic patients were 
on insulin therapy, 18 (19.7%) on oral hypoglycemic agents 
(OHA), and 23 (25.2%) were not on regular medications. 
The majority of patients, i.e., 56 (82.3%) patients, would 
not take their medications on hemodialysis days. Patients 
on OHA alone would not take their OHA on hemodialysis 
days, while patient on basal-bolus insulin, would omit 
the insulin dose before their hemodialysis session.
Table 2 compares the baseline blood parameters between 
DM-ESRD and NDM-ESRD patients. Both groups had a 
non-significant difference in terms of blood parameters 
apart from HbA1c, phosphate and albumin. Mean HbA1c 
among DM-ESRD patients was 7.4% with 37% having 
HbA1c less than 6.5% and 30% falling between 6.5% to 8%. 
Analysing the highly sensitive C-reactive protein (hs-CRP) 
as a surrogate marker for cardiac disease showed both 
groups having high hS-CRP levels with means of 8.91mg/L 
and 7.03 mg/L among DM-ESRD and NDM-ESRD patients 
respectively. Albumin levels were significantly lower 
among DM-ESRD patients, while phosphate levels were 
higher among NDM-ESRD patients.
In our DM-ESRD cohort, 13 (14.3%) took their OHA/insulin 
on hemodialysis days with 3 (3.3%) of patients reporting 
hypoglycemic symptoms during hemodialysis sessions. 
Almost all (94.7%) patients ate during hemodialysis. 
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Figure 1 illustrates mean blood glucose on hemodialysis 
days, which were significantly different (p<0.01) between 
DM-ESRD and NDM-ESRD patients. The mean (±SD) 
blood glucose was 9.33±2.7 mmol/L in DM-ESRD and 
6.07±0.85 mmol/L in NDM-ESRD. The mean fasting blood 
glucose was 7.9 mmol/L and 5.1 mmol/L in DM-ESRD and 
NDM-ESRD patients, respectively.
During the intra-dialytic period, the mean blood glucose 
was 8.1 mmol/L and 5.9 mmol/L in DM-ESRD and NDM-
ESRD groups, respectively. Among DM-ESRD, 61 (67.0%) 
of patients had readings within the suggested limits 
(4.4–8.5 mmol/L). Thirty (32.9%) patients recorded blood 
glucose more than 8.5 mmol/L. Among NDM-ESRD 
patients, the majority recorded values within the suggested 
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Table 1. Baseline socio-demographic and clinical characteristics of patients
Characteristics DM-ESRDn (%)
NDM-ESRD
n (%) Test statistic* p value
Sex
Male
Female
51 (56.0)
40 (44.0)
30 (52.6)
27 (47.4)
0.165 0.685
Race
Malay
Chinese 
Indian
79 (86.8)
1 (1.1)
11 (12.8)
52 (91.2)
1 (1.8)
4 (7.0)
1.078 0.583
BMI
Underweight (<18.5)
Normal (18.5 – 22.9)
Overweight (23.0 – 24.9)
Obese Class 1 (25.0 – 29.9)
Obese Class 2 (>30.0)
1 (1.1)
11 (12.8)
15 (16.5)
41 (45.1)
23 (25.3)
4 (7.0)
15 (26.3)
7 (12.3)
16 (28.1)
15 (26.3)
10.729 0.030***
BP Target Pre HD
Pre-HD BP (≤130/80)
Pre-HD BP (>130/80
12 (13.2)
79 (86.8)
4 (7.0)
53 (93.0)
1.383 0.240
BP Target Pre HD
Post HD BP (≤130/80)
Post HD BP (>130/80)
34 (37.4)
57 (62.6)
13 (22.8)
44 (77.2)
3.426 0.064
Smoking 
Yes
No
4 (4.4)
87 (95.6)
10 (17.5)
47 (82.5)
7.074 0.008***
Hypertension
Yes
No
90 (98.9)
1 (1.1)
54 (94.7)
3 (5.3)
2.311 0.128
IHD 
Yes
No
26 (28.6)
65 (71.4)
12 (21.1)
45 (78.9)
1.038 0.308
Gout
Yes
No
6 (6.6)
85 (93.4)
7 (12.3)
50 (87.7)
1.415 0.234
Stroke
Yes
No
5 (5.5)
86 (94.5)
2 (3.5)
55 (96.5)
0.307 0.580
Hyperlipidaemia
Yes
No
56 (61.5)
35 (38.5)
27 (47.4)
30 (52.6)
2.857 0.091
Mean (SD) Mean (SD) Test statistic** P value
Age (years)
Duration of HD (years)
BMI (kg/m2)
57.6 (11.1)
3.8 (3.1)
27.1 (4.4)
49.0 (11.2)
4.5 (3.3)
26.2 (6.6)
-4.590
1.310
-0.862
<0.001***
0.198
0.391
Table 1 shows the baseline sociodemographic and clinical characteristics of patients (n=148), values expressed as mean ± standard deviation. DM-ESRD, 
diabetic-end stage renal disease; NDM-ESRD, non diabetic end-stage-renal-disease; HD, hemodialysis; BP, blood pressure; BMI, body mass index. 
*Chi square test **Independent t-test ***P value<0.05
Table 2. Mean (SD) blood parameters comparing DM-ESRD and NDM-ESRD
Characteristics DM-ESRDMean (SD)
NDM-ESRD
Mean (SD) T statistic P value
Hemoglobin (g/dL)
HbA1c (%)
Total cholesterol (mmol/L)
LDL (mmol/L)
TG (mmol/L)
HDL (mmol/L)
HSCRP (mg/L)
Ferritin (ug/L)
Transferrin saturation (%)
Calcium (mmol/L)
Phosphate (mmol/L)
iPTH (pmol/L)
ALP (U/L)
Albumin (mmol/L)
10.47 (1.7)
7.40 (1.6)
4.8 (1.3)
2.97 (1.16)
2.30 (1.7)
0.97 (0.22)
8.91 (10.2)
554.1 (402)
23.96 (11.2)
2.16 (0.22)
1.85 (0.54)
73.6 (58.3)
176.32 (173.3)
38.3 (4.2)
10.38 (1.7)
5.41 (0.5)
5.0 (1.2)
3.10 (1.18)
2.04 (1.4)
1.08 (0.29)
7.03 (7.1)
665.2 (435)
24.82 (8.8)
2.19 (0.24)
2.18 (0.73)
103.7 (105.1)
143.37 (112.2)
40.1 (2.7)
-0.339
-10.845
1.003
0.664
-1.030
2.560
-1.310
1.497
0.526
0.883
2.893
1.889
-1.413
3.190
0.735
<0.001*
0.318
0.508
0.304
0.012
0.192
0.137
0.600
0.379
0.005*
0.063
0.159
0.002*
Table 2 shows the baseline blood parameters of patients (n=148), values expressed as mean ± standard deviation. HbA1c, glyclated hemoglobin A1c; 
LDL, low density lipoprotein; TG, triglycerides; HDL, high density lipoprotein; HSCRP, highly sensitive C-reactive protein; iPTH, intact parathyroid hormone; 
ALP, alkaline phosphatase. * p < 0.05.
intradialytic glucose limits. Eighteen (12%) patients i.e. 7 
(7.6%) with DM-ESRD and 11 (19.3%) with NDM-ESRD, 
experienced intradialytic asymptomatic hypoglycemia. 
This phenomenon which was seen predominantly 
among NDM-ESRD patients occurred mainly during the 
first hour of hemodialysis with mean pre-hemodialysis 
blood glucose of 4.3 mmol/L among NDM-ESRD patients. 
Post-hemodialysis trends showed a mean pre-prandial 
reading among DM-ESRD patients of 10.4 mmol/L and a 
mean post-prandial reading of 11.1 mmol/L. Among DM-
ESRD patients, 70 (77%) had blood glucose of more and 
equal to 7.0 mmol pre-prandially, while 65 (72%) had 
blood glucose more than 8.0 mmol/L post-prandially. 
Figure 1 shows that the DM-ESRD group had persistently 
high glucose level post-hemodialysis until the end of 
the day, which was not seen in the NDM-ESRD group.
Post-hemodialysis hyperglycemia (PHH)
PHH (defined as blood glucose ≥ 11.1 mmol/L 2-hours after 
first meal) post hemodialysis was prominent among DM-
ESRD patients, as almost 75 (82.4%) of them experienced 
more than 80% increase of blood sugar, compared to 
NDM-ESRD patients during the end of hemodialysis, odds 
ratio 4.5 (CI: 2.2 – 9.6) (Figure 2). However, among NDM-
ESRD patients, almost half of the patients, i.e. 25 (43.8%) 
experienced a reduction in blood sugar post hemodialysis 
as compared to only 14 (15.4%) of DM-ESRD patients.
Glycemic pattern on non-hemodialysis days 
On non-hemodialysis days (Figure 1), there were 
significant differences between blood sugar profiles 
among DM-ESRD and NDM-ESRD patients, where the 
mean (SD) blood glucose was 9.85 ± 3.1 mmol/L and 
6.0 ±0.88 mmol/L, respectively. In DM-ESRD patients, 
post-prandial hyperglycemia more or equal to 8.5 mmol/L 
were observed in 61 (67.0%) patients with 28 (30.8%) 
experiencing blood sugar more or equal to 11.1 mmol/L 
(mean preprandial 9.1 ± 3.1 mmol/L and post-prandial 
10.4 ± 3.3 mmol/L). 
Correlation between mean blood glucose and HbA1c 
In our population, there was a strong correlation between 
mean blood glucose and HbA1c among all patients 
with R2 = 0.73. However, among DM-ESRD patients, the 
correlation was moderate with R2 = 0.59.
Factors associated with PHH 
Table 3 demonstrates a simple logistic regression analysis 
of clinical characteristics and blood parameters associated 
with PHH. In this study, DM-ESRD, obesity, previous 
IHD, older age, high HbA1c, elevated hs-CRP and low 
Vol. 35 No. 1 May 2020
46
www.asean-endocrinejournal.org
Abdul Hanif Khan Yusof Khan, et al Post-Hemodialysis Hyperglycemia in End-Stage-Renal Disease
Figure 1. Glycemic patterns among DM-ESRD vs. NDM-ESRD during hemodialysis days and non-hemodialysis days. 
Legend: DM-ESRD shows more marked glucose fluctuations during hemodialysis days with prominent post-hemodialysis hyperglycemia coupled with 
persistent hyperglycemia until the end of the day. Glycemic fluctuations were not prominent during non-hemodialysis days in both DM-ESRD and NDM-
ESRD. Timing hemodialysis day: D1 = Fasting, D2 = Prior hemodialysis, D3 = 1st  hour hemodialysis, D4 = 2nd hour hemodialysis, D5 = 3rd hour hemodialysis, 
D6 = 4th hour hemodialysis, D7 = 2 hours post hemodialysis, before meal, D8 = 2hrs post meal, D9 = before dinner, D10 = 2 hours post dinner, D11= before 
sleep. Timing non-hemodialysis: ND1 = Fasting – before breakfast, ND2 = 2 hours  post breakfast, ND3 = before lunch, ND4 = 2 hours post lunch, ND5 = before 
dinner, ND6 = 2 hours post dinner, ND7 = before sleep.
Figure 2. Capillary glucose changes post hemodialysis 
sessions
Legend: Figure 2 showing the capillary glucose changes occurs post 
hemodialysis session between DM-ESRD and NDM-ESRD. In DM-ESRD, 
75 (82.4%) experienced more than 80% increased of blood sugar value, 
compared to NDM-ESRD during the end of hemodialysis with odds ratio 
of 4.5 (CI: 2.2 – 9.6).
albumin were associated with the risk of PHH. Table 4 
shows the final multivariate logistic regression model, 
the model is fit with R2 of 0.258. Increasing age of the 
patient are significant with adjusted odds ratio of 1.04, 
while DM-ESRD had adjusted odds ratio of almost three 
times higher than NDM-ESRD.
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Table 3. Factors associated with post haemodialysis hyperglycaemia (PHH) using simple logistic regression
PHH
Test statistic P Value Crude Odds ratio (95% CI)
Increase Decrease
Diabetes
Yes
No
74 (72.5)
28 (27.5)
17 (37.0)
29 (63.0)
3.989 <0.01
4.5 (2.2, 9.6)
Reference 
Gender
Female
Male
48 (47.1)
54 (52.9)
19 (41.3)
27 (58.7)
0.650 0.515
1.26 (0.63, 2.58)
Reference
Smoking
Yes 
No  
8 (7.8)
94 (92.2)
6 (13.0)
40 (87.0)
-0.991 0.322
0.56 (0.19, 1.82)
Reference
BMI (kg/m2)
Normal (18.5 – 22.9)
Underweight (<18.5)
Overweight (23.0 – 24.9)
Obese 1 (25.0 – 29.9)
Obese 2 (>30.0)
16 (15.7)
2 (2.0)
14 (13.7)
41 (40.2)
29 (28.4)
10 (21.7)
3 (6.5)
8 (17.4)
16 (34.8)
9 (19.6)
22.7
0.877
0.951
1.404
1.592
<0.01
0.380
0.342
0.160
0.111
Reference 
2.40 (0.34, 20.77)
2.63 (0.36, 23.37)
3.84 (0.59, 31.31)
4.83 (0.70, 41.37)
IHD
Yes
No
30 (29.4)
72 (70.6)
8 (17.4)
38 (82.6)
1.53 0.125
1.98 (0.86, 5.01)
Reference
Gout
Yes
No
8 (7.8)
94 (92.2)
5 (10.9)
41 (89.1)
-0.600 0.549
0.70 (0.22, 2.43)
Reference
Hyperlipidaemia
Yes
No
60 (58.8)
42 (41.2)
23 (50.0)
23 (50.0)
0.999 0.318
1.43 (0.71, 2.89)
Reference
Stroke
Yes 
No  
5 (4.9)
97 (95.1)
2 (4.3)
44 (95.7)
0.147 0.883
1.13 (0.23, 8.13)
Reference
Hypertension
Yes
No
100 (98.0)
2 (2.0)
44 (95.7)
2 (4.3)
0.0808 0.419
2.27 (0.27, 19.43)
Reference
Mean (SD)
Age (years)
Duration HD (years)
BMI (kg/m2)
HbA1c (%)
HSCRP (mg/L)
Ferritin (μg/L)
Albumin (mmol/L) 
Clearance (%)
LDL (mmol/L)
HDL (mmol/L)
HB (g/dL)
TG (mmol/L)
Transferrin saturation 
Calcium (mmol/L)
Phosphate (mmol/L)
ALP (U/L)
iPTH (pmol/L)
56.6 (12.0)
3.9 (3.1)
27.3 (5.1)
6.9 (1.6)
8.4 (8.3)
622.2 (413.1)
38.5 (4.0)
69.5 (9.0)
3.0 (1.2)
0.99 (0.2)
10.44 (1.7)
2.3 (1.8)
24.0 (10.2)
2.17 (0.21)
1.9 (0.6)
148.6 (108.0)
78.1 (67.6)
49.2 (10.2)
4.5 (3.4)
25.6 (5.8)
6.1 (1.5)
6.4 (6.1)
560.2 (421.7)
39.9 (3.0)
69.0 (9.4)
3.0 (1.0)
1.0 (0.3)
10.40 (1.7)
1.9 (1.1)
25.2 (10.9)
2.16 (0.24)
2.1 (0.7)
175.0 (154.4)
100.5 (102.4)
3.383
-0.983
1.756
2.613 
1.42
0.807
-2.109
0.260
0.115
-1.174
0.168
1.334
-0.611
0.336
-1.408
-1.169
-1.465
<0.01
0.326
0.079
<0.01
0.155
0.412
0.035
0.795
0.908
0.240
0.866
0.182
0.541
0.737
0.160
0.242
0.162
1.06 (1.03, 1.10)
0.95 (0.86, 1.06)
1.06 (0.99, 1.14)
1.44 (1.12, 1.94)
1.04 (0.99, 1.10)
1.00 (0.99,1.00)
0.89 (0.80, 9.88)
1.01 (0.97, 1.05)
1.02 (0.75, 1.39)
0.44 (0.11, 1.74)
1.02 (0.83, 1.25)
1.20 (0.94, 1.61)
0.99 (0.96, 1.02)
1.31 (0.26, 6.34)
0.68 (0.39,1.16)
0.99 (0.99, 1.00)
0.99 (0.99,1.00)
Table 3 shows simple logistic regression analysis of sociodemographic, clinical co-morbidities and blood parameters among patients in cohort (n=148) with 
post hemodialysis hyperglycemia (PHH). Diabetes, Body Mass Index (BMI) category, Ischemic Heart Disease (IHD), age, glycated hemoglobin (HbA1c), 
highly sensitive C-reactive protein (hs-CRP) and albumin were significant at P<0.15 to be included in multiple logistic regression.
Table 4. Multiple logistic regression analysis for factors associated with post hemodialysis hyperglycemia (PHH) (N=148)
Variable β SE Wald Adjusted OR (95% CI) P-Value
Diabetes
Age (years)
IHD
HBA1c (%)
Albumin (mmol/L)
HSCRP (mg/L)
1.08
0.041
0.584
0.004
-0.093
0.0152
0.56
0.019
0.515
0.176
0.065
0.031
1.951
2.157
1.134
0.026
-1.429
0.497
2.96 (1.01, 9.09)
1.04 (1.00, 1.08)
1.80 (0.68, 5.22)
1.00 (0.72, 1.44)
0.91 (0.80, 1.03)
1.02 (0.96, 1.08)
0.050*
0.031*
0.257
0.980
0.153
0.620
BMI (kg/m2)
Normal (Reference)
Underweight
Overweight
Obese
Obese Class 1
-
0.588
0.023
0.643
1.12
-
1.05
1.10
1.02
1.06
-
0.558
0.021
0.628
1.051
Reference
1.80 (0.22, 16.89)
1.02 (0.12, 10.28)
1.90 (0.25, 16.94)
3.06 (0.38, 29.24)
0.577
0.983
0.530
0.293
Table 4 shows multiple logistic regression analysis of significant factors associated with post hemodialysis hyperglycemia among ESRD patients during 
hemodialysis (HD) day. OR, odd ratio; HbA1c, glyclated hemoglobin; HSCRP, highly sensitive C-reactive protein; Ischemic Heart Disease (IHD) and BMI class. 
R2= 0.258 (Nagelkerke) *P<0.05.
DISCUSSION 
Cardiovascular disease is the leading cause of morbidity 
and mortality in ESRD particularly in diabetic patients, 
where the excessive cardiovascular risk may be attributed 
to underlying co-morbidities and population-based 
factors; however, these do not account for all the observed 
risk.4 Studies have shown that besides the average 
HbA1c (a marker for chronic hyperglycemia), short-
term glycemic variation (GV) is also an independent risk 
factors for diabetic complications.12–14 GV, which describes 
glycemic fluctuations or oscillations around a mean value, 
is an independent risk factor for diabetes-associated 
morbidity and mortality.15 Post-prandial hyperglycemia; 
among the main contributors to GV, similar to PHH, was 
shown to play a significant role in the pathophysiology 
of diabetic complications in terms of inducing oxidative 
stress and the inflammatory process.16,17 Hence, it is 
crucial to evaluate the glycemic pattern in hemodialysis 
patients, especially emphasizing PHH, as it is one of the 
main contributors to glycemic fluctuations.
In our study, DM-ESRD patients had more significant 
glycemic fluctuations compared to those with NDM-
ESRD. During hemodialysis days, we observed that 
PHH was fourfold higher in DM-ESRD compared to 
NDM-ESRD patients. An 80% rise in blood glucose post-
hemodialysis occurred in 82% of diabetic patients. This 
hyperglycaemia was subsequently persistent throughout 
the day. On the other hand, this persistent hyperglycemia 
post hemodialysis was not seen among NDM-ESRD 
patients. This shows that hemodialysis predisposes DM-
ESRD patients to constant hyperglycemia. Other patients 
exhibited lowered blood glucose levels in the first hour 
of hemodialysis, which subsequently became constant 
over the four hours of hemodialysis. This asymptomatic 
intradialytic hypoglycemia was observed in 18 (12.6%) 
patients, and more markedly seen in NDM-ESRD patients 
i.e., 11 (19.3%) patients. In the DM-ESRD patients, only 7 
(7.8%) of out of the 91 patients developed intradialytic 
hypoglycemia; and the majority occurred in the first 
hour of hemodialysis with a mean blood glucose pre-
hemodialysis of 5.4 mmol/L. Most of these patients were on 
insulin treatment. Although patients with NDM-ESRD had 
no significant glycemic fluctuations during hemodialysis, 
almost half experienced a reduction in blood sugar 
levels post-hemodialysis. Development of intra-dialytic 
hypoglycemia and reduction of blood sugar among ESRD 
patients even non-diabetic was an important observation, 
as currently there are no guidelines on management of 
insulin or OHA on hemodialysis days, which is left to the 
nephrologist’s discretion.7 However, we demonstrated 
that the number of patients developing intra-dialytic 
hypoglycemia was small compared to those developing 
PHH, which is similar to previous studies.18–20 Furthermore, 
among our population, all patients were encouraged to eat 
during hemodialysis to prevent episodes of hypoglycemia.
Our observations were similar to other studies on 
hemodialysis patients. Abe et al. showed that plasma 
glucose decreased with hemodialysis and hyperglycemic 
spikes were observed post hemodialysis which were 
attributed to decreased insulin due to hemodialysis 
clearance and/or the release of counter-regulatory 
hormones.6 Similar intradialytic glucose reduction and 
PHH were observed by Gai et al., which demonstrates 
PHH occurs 150 minutes post-hemodialysis.20 Kazempour-
Ardenilli et al., showed glycemic readings were lower on 
hemodialysis days as compared to non-hemodialyis days.18 
Both Mirani et al., and Jin et al., showed that GV was 
more pronounced on hemodialysis days, however, mean 
blood glucose was lower on hemodialysis days compared 
to non-hemodialysis days.11,19
This observation of intra-dialytic hypoglycemia coupled 
with significant PHH should prompt the nephrologist 
to adjust glycemic management of DM-ESRD patients. 
Possible administration of additional insulin or less 
hypoglycemic agents e.g., dipeptidyl-peptidase 4 inhibitors 
or glucagon-like-peptide analogs post-hemodialysis 
or on hemodialysis days will eventually help reduce 
glycemic fluctuations.6,21–23 Development of intradialytic-
hypoglycemia should be taken seriously because, as shown 
in our study and previous studies, a majority of these 
events were asymptomatic (role of autonomic neuropathy 
in long-standing diabetes).5,24 Events of intradialytic 
hypoglycemia were mostly asymptomatic in our study 
and previous studies, suggesting underlying autonomic 
neuropathy from long-standing diabetes. These might 
suggest the possibility of other undetected hypoglycemic 
events which may further aggravate glycemic fluctuations. 
Therefore, the role of additional intra-dialytic glucose 
monitoring should be further studied.
In our study, we report that PHH, as reported by SMBG, 
is more significant in patients with DM-ESRD, older 
age, obesity and previous IHD. Other associated blood 
parameters include high HbA1c, elevated hs-CRP and 
lower albumin. The association between HbA1c levels 
and glycemic fluctuations and mean blood glucose had 
been heavily investigated previously with conflicting 
results. Conversely, studies have shown that HbA1c has 
a weak correlation with glycemic fluctuations but has 
a significant relationship with chronic hyperglycemia 
and mean blood glucose.25–28 Interestingly, recent studies 
among Asian populations showed similar findings to our 
study where HbA1c correlates with glycemic variability 
indices.29,30 Notably, most of these studies exclude ESRD 
patients where HbA1c is a less reliable surrogate for 
glycemic control as it may falsely increase or decrease 
due to factors related to ESRD, e.g. anemia and uremia.7,31 
Anemia present in 42% of our population may have 
confounded our findings of 68% of patients with HbA1c 
less than 8%, with mean of 7.4% (reasonable control). The 
correlation between mean blood glucose and HbA1c in 
our population was moderate with R2 of 0.59, similar to 
other studies on DM-ESRD where the R2 is not more than 
0.50 compared to NDM-ESRD with R2 more than 0.80.27,32 
Nonetheless, HbA1c level more than 8.5% in DM-ESRD 
patients was related to increased mortality and should not 
deter clinicians from controlling the glucose level.31 
PHH is also associated with older age in which there is 
pancreatic beta cell dysfunction with limited capability to 
generate coupled with insulin resistance.33,34 Studies have 
shown that beta-cell dysfunction plays a significant role in 
explaining dysglycemia, where insufficient insulin secretion 
for accurate glycemic regulation may lead to glucose-
related metabolic disorders, resulting in increase glucose 
fluctuations and sustained hyperglycemia.35,36 Other studies 
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also showed similar findings where glucose fluctuations 
are more marked in the older age population.29,30
Previous IHD, high hs-CRP along with low albumin and 
relative obesity can be explained by the malnutrition-
inflammatory complex syndrome (MCIS), which a term 
coined to describe the chronic inflammatory state in 
hemodialysis patients, which is usually accompanied by 
malnutrition or protein-energy wasting (PEW).5 Oxidative 
stress and high inflammatory levels are associated with 
endothelial dysfunction and subsequently, micro and 
macro-angiopathy in diabetic patients, particularly 
resulting in cardiovascular complications.37 
We specifically looked at the inflammatory biomarker hs-
CRP to add prognostic information on cardiovascular risk 
in our population. A previous study evaluated the role of hs-
CRP and showed that there was a linear relationship with 
vascular risk; a value of less than 1mg/L (lower risk), 1 to 3 
mg/L (moderate risk) and more than 3mg/L (higher risk).38 
In hemodialysis patients, although elevated hs-CRP at a 
single time point is an important predictor of cardiovascular 
events, the values are not static and may reflect the chronic 
inflammatory process due to hemodialysis, intercurrent 
clinical events, decreased residual renal functions and 
PEW.39–41 A study done in hemodialysis patients showed 
that serum CRP levels increased annually during the 
follow up period.42 In our study, the mean hs-CRP in DM-
ESRD and NDM-ESRD patients were 8.91 mg/L and 7.03 
mg/L respectively, with only 41 (27.7%) of patients with 
level less 3 mg/L. This suggests that hemodialysis patients, 
regardless of their diabetic status, were in a constant state 
of inflammation, which predisposes them to a higher 
risk of a cardiovascular event. PEW, on the other hand, 
represented by low albumin, is common among patients 
undergoing maintenance hemodialysis and is by far the 
strongest risk factor for adverse outcomes and death.43 
A 10-year cohort study which evaluated serum albumin, 
C-reactive protein, and carotid atherosclerosis as predictors 
of 10-year mortality in hemodialysis patients showed that 
serum albumin concentration was superior as a predictor of 
mortality.44 However, in our cohort, the difference between 
38 mmol/L among patients experiencing PHH compared 
to 40 mmol/L maybe hard to appreciate in clinical setting. 
Nonetheless, by addressing the issue of malnutrition and 
chronic inflammation among hemodialysis patients, we 
may improve the occurrence of glycemic fluctuations and 
subsequently improve outcomes in these patients.
The first limitation of this study was its cross-sectional 
design and one-off blood sugar monitoring during 
hemodialysis and non-hemodialysis days. This design 
may not accurately represent the overall picture of the 
patients, as many factors can influence single snapshot 
monitoring. Another limitation was the usage of SMBG 
instead of continuous glucose monitoring system (CGMS) 
in assessing PHH. CGMS is preferable as SMBG can miss 
specific peaks and nadirs in glucose values.45,46 However, 
it is challenging to perform CGM in daily practice, given 
discomfort, cost, and the need for calibration compared to 
the SMBG. The practical aspect of SMBG in terms of easy 
availability, monitoring and interpretation, and lower cost 
makes it the preferred method in our population. We did 
not limit or measure dietary intake of patients during the 
study period, which makes it an additional confounding 
factor in the glycemic profile of the patients. Some previous 
studies restricted dietary intake or asked the patient to fast 
during hemodialysis to reduce confounding. However, 
doing so is not reflective of the normal day-to-day glucose 
fluctuations of patients, and allowing normal dietary 
intake reflects real-life data and consequently will allow 
meaningful alterations in management.
CONCLUSION 
DM-ESRD patients experienced more significant 
fluctuations of glucose level, in particular, PHH on 
hemodialysis day compared to those with NDM-ESRD. 
Other associated factors for PHH include older age group, 
previous IHD, obese patient, high HbA1c, and hs-CRP 
coupled with low albumin. Malnutrition-inflammatory-
complex syndrome, together with protein-energy wasting 
commonly seen among chronic hemodialysis patients, 
should be cornerstones in managing this group of patients as 
improving this phenomenon may improve glucose control 
and subsequently improve diabetes-related complications 
and mortality. Regular glucose monitoring via SMBG may 
provide valuable insights for treating physicians among 
this high-risk group.
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